VaxGen AIDSVAX Hopes Hinge On Positive Finding In Small Subgroups
VaxGen is pinning its hopes for the continued development of AIDSVAX on a positive finding in a small subgroup of black and Asian HIV patients after disappointing Phase III efficacy results in the general high-risk HIV population
You may also be interested in...
VaxGen is pushing back its BLA filing for the AIDS vaccine AIDSVAX until 2004 while it works to fulfill pre-approval manufacturing requirements
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials